Biotech Values

[genisi]

I think it is already clear that PCSK9 inhibition is very effective in lowering LDL-C and safety looks ok so far but too early to know. As for use, beyond narrow indications like FH this class will need to show benefit in decreasing CV and stroke risk and death in huge outcomes studies like you've mentioned, plus the drawback of being injectables.